If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 281 - 290 of 295
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Compare efficacy of Sonrotoclax + Zanubrutinib Vs Venetoclax + Obinutuzumab in untreated CLL
Protocol No
BEIGENE-BGB-11417-301
Categories
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Protocol No
GOG-3082-ACRIVON-ACR-368-201
Categories
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (RPS) (EORTC-1809: STRASS 2)
A randomized study investigating preoperative chemotherapy followed by surgery versus surgery alone in patients with high risk retroperitoneal sarcoma (STRASS2)
Protocol No
ECOG-EA7211
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study of EZM0414 in R/R MM and R/R DLBCL
Protocol No
EPIZYME-SET-101
Categories
A Phase Ib Study Of Combination Atr (M1774) And Bet Inhibition (Zen003694) To Exploit Arid1a Loss In Recurrent Ovarian And Endometrial Cancer
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Protocol No
NRG-GY031
Categories
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)
Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)
Protocol No
UNC-LCCC2234-PROCLAIM
Categories
A Pivotal Phase 3 Trial To Evaluate The Safety And Efficacy Of Clazakizumab For The Treatment Of Chronic Active Antibody-Mediated Rejection In Kidney Transplant Recipients
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Protocol No
NEPH-SAAD-IMAGINE
Categories
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and G
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Protocol No
SEAGEN-SGNDV-001-KN-D74
Categories
Every Day Counts: A Lifestyle Program for Women with Metastatic Breast Cancer
Every Day Counts: A Lifestyle Program for Women with Metastatic Breast Cancer
Protocol No
IIT-STOLLEY-EVERY-DAY-COUNTS-2
Categories
Microvascular Response to Local Heating in Stroke Survivors
Microvascular Response to Local Heating
Protocol No
PMR-IIT-DURAND-MRLH
Categories